WX-0593
Phase 3Small molecule
Qilu Pharmaceutical Co., Ltd.WX-0593 is one of 49 small molecule programs targeting Non-Small Cell Lung Cancer. It is currently in Phase 3.
2
Indications
6
Total Trials
2
Active Trials
48
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
414 competitors in Non-Small Cell Lung Cancer
#DrugCompanyPhaseTrials
1Zegfrovy
DDizal Pharmaceuticals
Phase 3
Nano-Crystalline Megestrol Acetate
Changchun GeneScience Pharmaceutical Co., Ltd.Phase 3
TY-9591
TTYK Medicines, Inc
Phase 3
WX-0593
Qilu Pharmaceutical Co., Ltd.Phase 3
Remeron
OOrganon and Co
Preclinical
Aqupla
Jiangsu Simcere Pharmaceutical Co., Ltd.Preclinical
Ftorafur
TThe First Affiliated Hospital with Nanjing Medical University
Preclinical
Vibramycin
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Preclinical
Treatment
GSKPreclinical
PD-1 Inhibitors
BBioNTech US Inc.
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Non-Small Cell Lung Cancer4 trials
Advanced Solid Tumor1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for WX-0593. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details